DYN · Dyne Therapeutics Inc
-
-
| ISIN | US26818M1080 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| PE Ratio | None |
|---|---|
| Beta | 1.21 |
| Market Cap | 1B |
| Target Price | 47.8571 |
| Dividend Yield | None |
ABOUT
Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Learn More